Cara Therapeutic stock page - price, fundamentals, dividends - iOCharts

Ticker
CARA

Price
8.62
Stock movement down
-0.51 (-5.59%)
Company name
Cara Therapeutic
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
461.96M
Ent value
460.35M
Price/Sales
17.85
Price/Book
2.26
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-24.10%
1 year return
-40.35%
3 year return
-27.10%
5 year return
-19.51%
10 year return
-
Last updated: 2022-07-01

DIVIDENDS

CARA does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales17.85
Price to Book2.26
EV to Sales17.79

FINANCIALS

Per share

Loading...
Per share data
Current share count53.59M
EPS (TTM)-1.76
FCF per share (TTM)-1.18

Income statement

Loading...
Income statement data
Revenue (TTM)25.88M
Gross profit (TTM)23.80M
Operating income (TTM)-95.51M
Net income (TTM)-92.89M
EPS (TTM)-1.76
EPS (1y forward)-0.04

Margins

Loading...
Margins data
Gross margin (TTM)91.96%
Operating margin (TTM)-369.02%
Profit margin (TTM)-358.88%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash21.36M
Net receivables3.63M
Total current assets151.76M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets223.87M
Accounts payable5.59M
Short/Current long term debt3.25M
Total current liabilities18.30M
Total liabilities19.75M
Shareholder's equity204.12M
Net tangible assets205.57M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-61.89M
Capital expenditures (TTM)222.00K
Free cash flow (TTM)-62.11M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-45.51%
Return on Assets-41.49%
Return on Invested Capital-45.11%
Cash Return on Invested Capital-30.17%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open9.02
Daily high9.28
Daily low8.26
Daily Volume670K
All-time high29.19
1y analyst estimate25.00
Beta1.22
EPS (TTM)-1.76
Dividend per share-
Ex-div date-
Next earnings date8 Aug 2022

Downside potential

Loading...
Downside potential data
CARAS&P500
Current price drop from All-time high-70.47%-20.19%
Highest price drop-80.50%-56.47%
Date of highest drop27 Jun 20169 Mar 2009
Avg drop from high-43.93%-11.36%
Avg time to new high118 days12 days
Max time to new high948 days1805 days
COMPANY DETAILS
CARA (Cara Therapeutic) company logo
Marketcap
461.96M
Marketcap category
Small-cap
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Employees
84
SEC filings
CEO
Derek Chalmers
Country
USA
City
Stamford
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Cara Therapeutics Inc (NASDAQ: CARA) announced topline results from its Phase 2 proof-of-concept trial (KOMFORT) of difelikefalin for moderate-to-severe pruritus in patients with notalgia paresthetica...
June 30, 2022
– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) – – Onset of action seen at Week 1 and sustained through Week 8 – – Statistical sign...
June 30, 2022
In this article, we discuss the 10 best CBD stocks to invest in. You can skip our detailed analysis of these stocks and the current market situation, and go directly to 5 Best CBD Stocks To Invest In....
June 6, 2022
A look at the shareholders of Cara Therapeutics, Inc. ( NASDAQ:CARA ) can tell us which group is most powerful...
May 23, 2022
STAMFORD, Conn., May 17, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of p...
May 17, 2022
Cara (CARA) delivered earnings and revenue surprises of 7.14% and 69.72%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
May 9, 2022
KORSUVA™ (difelikefalin) injection U.S. commercial launch began in April 2022 and is tracking to expectation Kapruvia® (difelikefalin) approved by European Commission for the treatment of moderate-to-...
May 9, 2022
Vericel Corporation (VCEL) delivered earnings and revenue surprises of 0% and 6.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
May 4, 2022
STAMFORD, Conn., May 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of p...
May 3, 2022
STAMFORD, Conn., April 29, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
April 29, 2022
Next page